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Bacteria gain antibiotic resistance genes by horizontal acquisition of  ? ?
mobile genetic elements (MGE) from other lineages. Newly acquired  ? ?
MGEs are often poorly adapted causing intragenomic conflicts, resolved  ? ?
by compensatory adaptation of the chromosome, the MGE or reciprocal  ? ?
coadaptation. The footprints of such intragenomic coevolution are  ? ?
present in bacterial genomes, suggesting an important role promoting  ? ?
genomic integration of horizontally acquired genes, but direct  ? ?
experimental evidence of the process is limited. Here we show adaptive  ? ?
modulation of tetracycline resistance via intragenomic coevolution  ? ?
between Escherichia coli and the multi-drug resistant (MDR) plasmid  ? ?
RK2. Tetracycline treatments, including monotherapy or combination  ? ?
therapies with ampicillin, favoured de novo chromosomal resistance  ? ?
mutations coupled with mutations on RK2 impairing the plasmid- ? ?
encoded tetracycline efflux-pump. These mutations together provided  ? ?
increased tetracycline resistance at reduced cost. Additionally, the  ? ?
chromosomal resistance mutations conferred cross-resistance to  ? ?
chloramphenicol. Reciprocal coadaptation was not observed under  ? ?
ampicillin-only or no antibiotic selection. Intragenomic coevolution can  ? ?
create genomes comprised of multiple replicons that together provide  ? ?
high-level, low-cost resistance, but the resulting co-dependence may  ? ?
limit the spread of coadapted MGEs to other lineages.    ? ?
  ? ?
   ? ?
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Horizontal gene transfer (HGT) is a fundamental process in bacterial evolution  ? ?
that accelerates adaptation by sharing ecologically important accessory traits  ? ?
between lineages1. These accessory traits are themselves frequently located  ? ?
on semi-autonomous mobile genetic elements (MGE), such as conjugative  ? ?
plasmids, that encode genes for their own replication, partition and horizontal  ? ?
transfer2,3. Conjugative multidrug resistance (MDR) plasmids, encoding  ? ?
antibiotic resistance genes (ARG) against multiple classes of antibiotics, are  ? ?
of particular clinical concern since they allow instantaneous acquisition of  ? ?
MDR phenotypes and thus potentiate the rapid emergence of MDR bacterial  ? ?
pathogens4,5. Newly acquired conjugative plasmids are often costly since the  ? ?
plasmid is unlikely to be well adapted to the new genetic background, causing  ? ?
intragenomic conflict6. The cost of plasmid carriage is likely to arise due to the  ? ?
metabolic burden of maintaining, transcribing and translating plasmid genes7,  ? ?
as well as via disruption of cellular homeostasis caused by gene regulatory  ? ?
interference between chromosomal and plasmid regulators8,9, and cytotoxic  ? ?
effects of plasmid gene products6.   ? ?
  ? ?
An important route to resolving this intragenomic conflict is compensatory  ? ?
evolution to ameliorate the cost of plasmid acquisition10. Experimental  ? ?
evolution suggests that compensatory evolution can arise via mutations  ? ?
located on either the chromosome or the plasmid, or via intragenomic  ? ?
coevolution involving both plasmid and chromosome mutations8,9,11,12.  ? ?
Comparative genomics suggests a key role for compensatory evolution in  ? ?
natural bacterial populations, potentially stabilising MDR plasmids within  ? ?
lineages and thus allowing the evolutionary emergence by HGT of MDR  ? ?
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pathogens13. A key outstanding question is how the mode of compensatory  ? ?
evolution following MDR plasmid acquisition varies with antibiotic treatment.  ? ?
Here we experimentally evolved Escherichia coli MG1655 carrying the MDR  ? ?
plasmid RK2 (encoding tetracycline and ampicillin resistance genes) under a  ? ?
range of antibiotic treatment regimes including no antibiotic, mono- and  ? ?
combination-therapies of tetracycline and ampicillin. Following 530  ? ?
generations of selection we quantified evolved changes in antibiotic  ? ?
resistance and fitness, and used genome sequencing to determine the  ? ?
genetic bases of the observed adaptation.   ? ?
  ? ?
Results  ? ?
Thirty independent isogenic populations of E. coli MG1655 carrying the MDR  ? ?
plasmid RK214, which encodes resistances to tetracycline (TET) and ampicillin  ? ?
(AMP), were experimentally evolved for ~530 generations (80 days), under  ? ?
five antibiotic treatments (six independently evolving lines per treatment): no  ? ?
antibiotic (N), AMP (A), TET (T), AMP plus TET (AT), and 24 hour cycling  ? ?
between AMP and TET (A/T) (see methods). Plasmids remained at high  ? ?
frequency in all populations for the duration of the selection experiment.  ? ?
Plasmid-free segregants were only observed at very low frequency in two of  ? ?
the six populations from treatment N (Supplementary Fig. 1), whereas  ? ?
transposition of resistance genes from RK2 onto the host’s chromosome was  ? ?
never observed.   ? ?
  ? ?
To test for changes in antibiotic resistance profiles following evolution we first  ? ?
determined the minimum inhibitory concentration (MIC) of evolved lineages to  ? ?
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TET and AMP. The susceptibility of the evolved strains to antibiotics differed  ? ?
between treatments (Fig. 1a). We observed a four-fold increase in TET MIC in  ? ?
evolved strains from the T and AT treatments and a small increase in lineages  ? ?
that had evolved under the cycling A/T treatment compared with the ancestral  ? ?
MG1655 with ancestral RK2 (Anc-RK2), whereas evolved strains from  ? ?
treatments N and A showed no change in tetracycline MIC (ANOVA, F5,30 =  ? ?
6.103, p < 0.001; Post-hoc Tukey Tests, Anc-RK2:T p < 0.001, Anc-RK2:AT p  ? ?
< 0.01, Anc-RK2:N p = 0.525, Anc-RK2:A p = 0.783). By contrast, we  ? ?
observed no change in resistance to AMP in any treatment (ANOVA, F5,30 =  ? ?
1.212, p = 0.327), possibly due to a lower relative selection pressure imposed  ? ?
by the concentration of AMP used in the experiment compared to the  ? ?
concentration of TET15. Interestingly, TET selection led to the evolution of  ? ?
bacteria that were cross-resistant to chloramphenicol (CML), although the  ? ?
extent of the evolved cross-resistance varied between treatments (ANOVA,  ? ?
F5,30 = 24.25, p < 0.001); with CML MIC increasing 8-, 4-, and 2-fold in T, AT,  ? ?
A/T treatments, respectively. Consistent with CML cross-resistance being a  ? ? ?
correlated response to TET selection, evolved strains from both the N and A  ? ? ?
treatments remained equally sensitive to CML as the ancestral MG1655(RK2)  ? ? ?
(Post-hoc Tukey Tests, Anc-RK2:N p = 0.975, Anc-RK2:A p = 0.993). Thus  ? ? ?
whereas T and AT treatments, and to a lesser extent the cycling A/T  ? ? ?
treatment, led to the evolution increased TET resistance and cross-resistance  ? ? ?
to CML, evolved lineages from the N and A treatments showed no change in  ? ? ?
their resistance profile.  ? ? ?
  ? ? ?
 6 
To examine the genetic bases of evolved changes in resistance we next  ? ? ?
obtained whole genome sequences for one randomly selected clone per  ? ? ?
population. Excluding hypermutators, evolved clones had acquired between 2  ? ? ?
and 11 mutations, located exclusively on the chromosome in non-TET  ? ? ?
treatments (C, N, A), and on both the chromosome and plasmid in the  ? ? ?
treatments including TET (T, AT, A/T) (Supplementary Fig. 2, Supplementary  ? ? ?
Table 1). Of all the observed mutations 13.2% were synonymous and 19%  ? ? ?
were intergenic, the remaining non-synonymous mutations (67.8%) comprised  ? ? ?
missense mutations (42.8%), frameshifts (10.6%), insertion sequences (5.6%)  ? ? ?
and gene deletions (5.4%), and these were analysed further. While the  ? ? ?
variance in the number of non-synonymous mutations did not differ between  ? ? ?
treatments (Analysis of multivariate homogeneity of group variances excluding  ? ? ?
hypermutators F5,26 = 1.8617, p = 0.1358), the loci affected by non- ? ? ?
synonymous mutations did vary between treatments (Permutational ANOVA,  ? ? ?
permutation test: F5,26 = 2.5231, p < 0.01, Bonferroni corrected). Clones that  ? ? ?
had evolved under TET selection (T, AT, A/T) had significantly different sets  ? ? ?
of non-synonymous mutations compared to evolved clones from the other  ? ? ?
treatments (C, N, A) (permutation test: F1,30 = 6.9463, p < 0.01, Bonferroni  ? ? ?
corrected), with a larger genetic distance between TET and non-TET  ? ? ?
treatments than within these treatment groups (Fig. 2a). Thus TET-selected  ? ? ?
lineages followed an evolutionary trajectory distinct from non-TET-selected  ? ? ?
lineages, leading to mutations on both the chromosome and the plasmid,  ? ? ?
which suggest that TET selection favoured bacteria-plasmid coadaptation.  ? ? ?
  ? ? ?
 7 
Strikingly parallel mutations were observed between independent replicate  ? ? ?
populations both within and between TET-containing treatments (Fig. 2b).  ? ? ?
Highly parallel mutations are likely to represent adaptive evolution at these  ? ? ?
loci, and because mutations at these loci were not observed in the  ? ? ?
populations from the N and A treatments, these mutations were likely to be  ? ? ?
TET-specific adaptations. Mutations in the chromosomal genes ompF (16 out  ? ? ?
of 18 clones), and ychH (16 out of 18 clones) showed strong locus-level  ? ? ?
parallelism within all three TET-containing treatments. Mutations in ompF,  ? ? ?
encoding a major non-specific diffusion porin16, were all predicted loss-of- ? ? ?
function mutations, including the insertion of IS elements, frameshifts or  ? ? ?
premature stop codons. The loss of OmpF in E. coli reduces membrane  ? ? ?
permeability, including to antibiotics, and consequently is known to increase  ? ? ?
resistance to a wide spectrum of antibiotics17 including TET and CML18,19.  ? ? ?
Deletion of ompF (E. coli K-12 ǻompF JW091220) significantly increased  ? ? ?
resistance to TET without the RK2 (t9.09 = 4.2836, p < 0.01), and further  ? ? ?
increased TET resistance when carrying RK2 (Two-way ANOVA Interaction  ? ? ?
F1,20 = 14.724, p < 0.01; Supplementary Fig. 4a). Parallel loss of function  ? ? ?
mutations (IS elements and frameshifts) in ychH were observed across all the  ? ? ?
TET treatments. YchH is a hypothetical stress-induced inner membrane  ? ? ?
protein21,22, but deletion of ychH (E. coli K-12 ǻychH JW119620) did not  ? ? ?
significantly increase the resistance to TET with or without the plasmid  ? ? ?
(Supplementary Fig. 4b), suggesting that this general stress response may  ? ? ?
not be required under TET selection and is consequently selected against.   ? ? ?
  ? ? ?
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Mutations in several loci observed in the T and AT treatments were not  ? ? ?
present in the cycling A/T treatment. These included mutations in both acrR  ? ? ?
(10 out of 12 clones) and adhE (9 out of 12 clones). Mutations in adhE were  ? ? ?
extensively parallel at the nucleotide level, with 8 clones from independent  ? ? ?
populations all having the same missense SNP in the ethanol dehydrogenase  ? ? ?
domain23. The phenotypic significance of these mutations is unclear due to  ? ? ?
the multiple roles assigned to this protein, including multiple metabolic  ? ? ?
pathways24, but intriguingly the AdhE protein is known to exhibit binding  ? ? ?
activity to the 30S ribosome25, the primary TET target. The acrR gene  ? ? ?
encodes a repressor of AcrAB multidrug efflux pump26, the majority of  ? ? ?
mutations in acrR are predicted loss of function mutations, with IS elements  ? ? ?
and frameshifts observed in evolved strains. The deletion of acrR results in  ? ? ?
the overexpression of acrAB leading to MDR phenotypes27,28. Deletion of acrR  ? ? ?
(E. coli K-12 ǻacrR JW045320) alone did not significantly increase resistance  ? ? ?
to TET (t9.32 = -0.591, p = 0.339), but when combined with the RK2 plasmid  ? ? ?
did allow significantly increased growth in TET (t6.4 = 3.665, p < 0.01,  ? ? ?
Supplementary Fig. 4c). These findings are consistent with the higher TET  ? ? ?
resistance of evolved clones from the T and AT treatments versus the A/T  ? ? ?
treatment (Fig. 1a) and reflect overall weaker TET selection under the A/T  ? ? ?
cycling compared to the T and AT treatments where TET selection was  ? ? ?
constant. Interestingly, stronger TET selection appeared to constrain evolution  ? ? ?
at chromosomal loci not involved in resistance. For example, we observed  ? ? ?
highly parallel loss of function mutation in the flagellum operon in the A, N and  ? ? ?
A/T treatments, but only rarely observed mutations at these loci in T and AT  ? ? ?
treatments. Loss of the flagellar motility is a commonly observed adaptation of  ? ? ?
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E. coli to growth in liquid media29 and this may have been impeded by clonal  ? ? ?
interference or negative epistasis with chromosomal resistance mutations in  ? ? ?
populations under strong TET selection. Consistent with this, whereas  ? ? ?
evolved clones from the N and A treatments increased in fitness relative to the  ? ? ?
plasmid-free ancestor in antibiotic-free media, such fitness gains were not  ? ? ?
observed in evolved clones from the TET-containing treatments  ? ? ?
(Supplementary Fig. 5).  ? ? ?
  ? ? ?
To confirm that TET selection had led to the evolution of chromosomal  ? ? ?
resistance we next cured evolved strains of their plasmids and quantified  ? ? ?
resistance30. Evolved strains carrying putative chromosomal resistance  ? ? ?
mutations displayed increased TET (ANOVA, F5,30 = 42.63, p < 0.001), AMP  ? ? ?
(ANOVA, F5,30 = 12.55, p < 0.001) and CML (ANOVA, F5,30 = 35.88, p <  ? ? ?
0.001) resistance (Fig. 1b). Across all tested antibiotics, evolved clones  ? ? ?
carrying both ompF and acrR mutations had significantly increased resistance  ? ? ?
compared to the ancestral MG1655 (Post-hoc Tukey Tests, all p < 0.05),  ? ? ?
whereas cured evolved strains without either of these mutations (i.e. from the  ? ? ?
N and A treatments) did not (Post-hoc Tukey Tests, all p > 0.05). Interestingly,  ? ? ?
cured evolved clones from the cycling A/T treatment that carried only  ? ? ?
mutations in ompF but not in acrR showed marginally increased resistance to  ? ? ?
both TET and CML, but no detectable increase in AMP resistance, relative to  ? ? ?
MG1655. Thus TET selection favoured the de novo evolution of chromosomal  ? ? ?
resistance despite pre-existing plasmid-encoded TET resistance, and these  ? ? ?
chromosomal resistance mutations are responsible for the observed cross- ? ? ?
resistance to CML.   ? ? ?
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  ? ? ?
We observed parallel mutations on the plasmid exclusively in evolved clones  ? ? ?
from the TET-containing treatments (T, AT, and A/T). These mutations  ? ? ?
occurred in tetA/tetR (18 out of 18 clones; tetA: 13, tetR: 2, both: 3, Fig. 2b)  ? ? ?
which encode the tetracycline-specific efflux pump. The expression tetA is  ? ? ?
tightly regulated by the repressor tetR in the absence of tetracycline31,32.  ? ? ?
Mutations in tetA were dispersed throughout the gene, affecting the protein’s  ? ? ?
transmembrane, periplasmic and cytoplasmic domains33. Three of the five  ? ? ?
mutations observed in tetR are in direct contact with or in close proximity to  ? ? ?
the tetracycline binding pocket34, while the other two mutations are located in  ? ? ?
the central scaffolding of the protein, suggesting that they are likely to  ? ? ?
interfere with activity of the tetR repressor. Evolved plasmids carrying  ? ? ?
mutations in tetA or tetR displayed reduced resistance to TET in the ancestral  ? ? ?
MG1655 background compared to ancestral RK2 (Fig. 1d, ANOVA, F5,30 =  ? ? ?
4.586, p < 0.01). Consistent with reduced efficacy of plasmid-encoded  ? ? ?
resistance in evolved lineages with tetA/tetR mutations, when we replaced the  ? ? ?
evolved plasmid with ancestral RK2, this led to increased TET resistance  ? ? ?
(ANOVA, F5,30 = 71.86, p < 0.001, Anc-RK2:T,AT,A/T all p < 0.05).   ? ? ?
  ? ? ?
Our data suggest that evolved strains from TET-containing treatments  ? ? ?
adapted their resistance to TET by acquisition of weak chromosomal  ? ? ?
resistance mutations in combination with mutations that reduced the efficacy  ? ? ?
of the plasmid-encoded TET efflux pump. To understand the evolutionary  ? ? ?
benefits of this counterintuitive dual resistance strategy we first compared the  ? ? ?
effect of chromosomal background (evolved or ancestral) and plasmid  ? ? ?
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genotype (evolved or ancestral) on growth in the presence of 10 ȝg/ml TET  ? ? ?
(i.e., the concentration used in our selection experiment). The evolved  ? ? ?
chromosomal background carrying resistance mutations displayed a  ? ? ?
significantly shortened lag phase compared to the ancestral chromosomal  ? ? ?
background, irrespective of the plasmid genotype (Supplementary Fig. 6;  ? ? ?
ANOVA, F3,56 = 76.92, p < 0.001; Post-hoc Tukey Tests, Evolved  ? ? ?
Host:Ancestral Host all p < 0.001). This suggests that chromosomal  ? ? ?
resistances reducing membrane permeability to antibiotics allowed evolved  ? ? ?
strains to start growing faster in the presence of TET.   ? ? ?
  ? ? ?
Whereas evolved bacteria grew equally well with evolved or ancestral  ? ? ?
plasmids, ancestral bacteria displayed impaired growth with evolved  ? ? ?
compared to ancestral plasmids (Supplementary Fig. 6; Max OD, W = 93, p <  ? ? ?
0.01). This is consistent with the mutations in tetA/tetR reducing resistance  ? ? ?
but importantly confirms that this reduction is not evident when in combination  ? ? ?
with the chromosomal resistance mutations, which appear to compensate for  ? ? ?
the reduced efficacy of the plasmid-encoded efflux pump.   ? ? ?
  ? ? ?
We next competed evolved bacteria with either the evolved or ancestral  ? ? ?
plasmid against the ancestral MG1665(RK2) to compare the costs of carrying  ? ? ?
each plasmid genotype. The ancestral plasmid displayed a significantly higher  ? ? ?
cost than the evolved plasmid in the evolved chromosomal background  ? ? ?
(Supplementary Fig. 7, t25.71 = -2.287, p < 0.05). This suggests that the  ? ? ?
mutations to tetR/tetA ameliorate the cost of plasmid carriage but at the price  ? ? ?
of reduced efficacy of TET efflux. This is consistent with previous studies  ? ? ?
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showing a high cost of expressing the specific tetracycline efflux pump35.  ? ? ?
Taken together with the growth data, this suggests that although mutations to  ? ? ?
tetA/tetR reduce growth under tetracycline in the ancestral chromosomal  ? ? ?
background, they have minimal effect on resistance in the evolved  ? ? ?
chromosomal background due to the reduced membrane permeability and  ? ? ?
additional efflux systems expressed in the evolved chromosomal background  ? ? ?
carrying mutations in ompF and acrR, leading to high resistance and a  ? ? ?
lowered cost of plasmid carriage. This suggests that the chromosomal  ? ? ?
resistance mutations must have been gained prior to the mutations in the  ? ? ?
plasmid-encoded tetracycline efflux pump. To test this, for one population  ? ? ?
(AT2) we tracked the frequency over time of an observed IS-insertion in ompF  ? ? ?
by PCR and then determined by sequencing when these genotypes acquired  ? ? ?
mutations in the tetA/tetR genes. Consistent with the hypothesised order of  ? ? ?
mutations, the IS-insertion in ompF was first detected at transfer 8 and had  ? ? ?
swept to fixation by transfer 32, whereas mutations in tetA/tetR were not  ? ? ?
observed in this ompF::IS background until transfer 32 (supplementary figure  ? ? ?
8).  ? ? ?
  ? ? ?
Discussion  ? ? ?
Our current model of bacterial evolution suggests that horizontal acquisition of  ? ? ?
ARGs accelerates resistance evolution by providing bacteria with ready-made  ? ? ?
resistance mechanisms, bypassing the requirement for rare de-novo  ? ? ?
mutations1. However, recent population genomic data suggesting that  ? ? ?
lineages independently acquire and then subsequently coevolve with MDR  ? ? ?
plasmids13,36,37 imply a more dynamic evolutionary process. Consistent with  ? ? ?
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this, here we show here that gaining an ARG can be just the starting point in  ? ? ?
the evolution of resistance and, due to the costs of expressing horizontally  ? ? ?
acquired ARGs, does not preclude subsequent de novo evolution of  ? ? ?
chromosomal resistance. Evolved strains from TET-containing treatments  ? ? ?
gained chromosomal resistance mutations reducing membrane permeability  ? ? ?
and enhancing efflux of TET and providing cross-resistance to other  ? ? ?
antibiotics, shortening lag phase in the presence of TET. These mutations  ? ? ?
also reduced the need for a fully operational plasmid-encoded tetracycline  ? ? ?
efflux pump, expression of which is highly costly35, allowing plasmid mutations  ? ? ?
in the TET efflux pump and its regulator which reduced the cost of plasmid- ? ? ?
encoded resistance. A consequence of this intragenomic coevolution is that  ? ? ?
the increased TET resistance of evolved strains from T, AT and A/T  ? ? ?
treatments required the action of both the chromosomal- and plasmid- ? ? ?
encoded resistances, which together acted multiplicatively. Thus intragenomic  ? ? ?
coevolution can lead to the evolution of bacterial genomes comprised of co- ? ? ?
dependent replicons, limiting the potential for onward transmission of the  ? ? ?
plasmid due to the weaker resistance it now encodes in other lineages.   ? ? ?
  ? ? ?
References  ? ? ?
1. Jain, R., Rivera, M. C., Moore, J. E. & Lake, J. A. Horizontal Gene Transfer  ? ? ?
Accelerates Genome Innovation and Evolution. Mol. Biol. Evol. 20, 1598– ? ? ?
1602 (2003).  ? ? ?
2. Frost, L. S., Leplae, R., Summers, A. O. & Toussaint, A. Mobile genetic  ? ? ?
elements: the agents of open source evolution. Nat. Rev. Microbiol. 3, 722– ? ? ?
732 (2005).  ? ? ?
 14 
3. Norman, A., Hansen, L. H. & S?rensen, S. J. Conjugative plasmids: vessels  ? ? ?
of the communal gene pool. Philos. Trans. R. Soc. B Biol. Sci. 364, 2275– ? ? ?
2289 (2009).  ? ? ?
4. Svara, F. & Rankin, D. J. The evolution of plasmid-carried antibiotic  ? ? ?
resistance. BMC Evol. Biol. 11, 130 (2011).  ? ? ?
5. Carattoli, A. Plasmids and the spread of resistance. Int. J. Med. Microbiol.  ? ? ?
303, 298–304 (2013).  ? ? ?
6. Baltrus, D. A. Exploring the costs of horizontal gene transfer. Trends Ecol.  ? ? ?
Evol. 28, 489–495 (2013).  ? ? ?
7. Diaz Ricci, J. C. & Hernández, M. E. Plasmid Effects on Escherichia coli  ? ? ?
Metabolism. Crit. Rev. Biotechnol. 20, 79–108 (2000).  ? ? ?
8. Harrison, E., Guymer, D., Spiers, A. J., Paterson, S. & Brockhurst, M. A.  ? ? ?
Parallel Compensatory Evolution Stabilizes Plasmids across the  ? ? ?
Parasitism-Mutualism Continuum. Curr. Biol. 25, 2034–2039 (2015).  ? ? ?
9. San Millan, A., Toll-Riera, M., Qi, Q. & MacLean, R. C. Interactions  ? ? ?
between horizontally acquired genes create a fitness cost in Pseudomonas  ? ? ?
aeruginosa. Nat. Commun. 6, (2015).  ? ? ?
10. Harrison, E. & Brockhurst, M. A. Plasmid-mediated horizontal gene  ? ? ?
transfer is a coevolutionary process. Trends Microbiol. 20, 262–267 (2012).  ? ? ?
11. Porse, A., Schønning, K., Munck, C. & Sommer, M. O. A. Survival and  ? ? ?
Evolution of a Large Multidrug Resistance Plasmid in New Clinical Bacterial  ? ? ?
Hosts. Mol. Biol. Evol. msw163 (2016). doi:10.1093/molbev/msw163  ? ? ?
12. Loftie-Eaton, W. et al. Evolutionary Paths that Expand Plasmid Host- ? ? ?
Range: Implications for Spread of Antibiotic Resistance. Mol. Biol. Evol.  ? ? ?
msv339 (2015). doi:10.1093/molbev/msv339  ? ? ?
 15 
13. McNally, A. et al. Combined Analysis of Variation in Core, Accessory  ? ? ?
and Regulatory Genome Regions Provides a Super-Resolution View into  ? ? ?
the Evolution of Bacterial Populations. PLOS Genet. 12, e1006280 (2016).  ? ? ?
14. Pansegrau, W. et al. Complete Nucleotide Sequence of Birmingham  ? ? ?
IncPĮ Plasmids: Compilation and Comparative Analysis. J. Mol. Biol. 239,  ? ? ?
623–663 (1994).  ? ? ?
15. Bottery, M. J., Wood, A. J. & Brockhurst, M. A. Selective conditions for  ? ? ?
a multidrug resistance plasmid depend on the sociality of antibiotic  ? ? ?
resistance. Antimicrob. Agents Chemother. AAC.02441-15 (2016).  ? ? ?
doi:10.1128/AAC.02441-15  ? ? ?
16. Cowan, S. W. et al. Crystal structures explain functional properties of  ? ? ?
two E. coli porins. Nature 358, 727–733 (1992).  ? ? ?
17. Blair, J. M. A., Webber, M. A., Baylay, A. J., Ogbolu, D. O. & Piddock,  ? ? ?
L. J. V. Molecular mechanisms of antibiotic resistance. Nat. Rev. Microbiol.  ? ? ?
13, 42–51 (2015).  ? ? ?
18. Cohen, S. P., McMurry, L. M., Hooper, D. C., Wolfson, J. S. & Levy, S.  ? ? ?
B. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistant (Mar)  ? ? ?
Escherichia coli selected by tetracycline or chloramphenicol: decreased  ? ? ?
drug accumulation associated with membrane changes in addition to OmpF  ? ? ?
reduction. Antimicrob. Agents Chemother. 33, 1318–1325 (1989).  ? ? ?
19. Thanassi, D. G., Suh, G. S. & Nikaido, H. Role of outer membrane  ? ? ?
barrier in efflux-mediated tetracycline resistance of Escherichia coli. J.  ? ? ?
Bacteriol. 177, 998–1007 (1995).  ? ? ?
 16 
20. Baba, T. et al. Construction of Escherichia coli K-12 in-frame, single- ? ? ?
gene knockout mutants: the Keio collection. Mol. Syst. Biol. 2, 2006.0008  ? ? ?
(2006).  ? ? ?
21. Lee, J., Hiibel, S. r., Reardon, K. f. & Wood, T. k. Identification of  ? ? ?
stress-related proteins in Escherichia coli using the pollutant cis- ? ? ?
dichloroethylene. J. Appl. Microbiol. 108, 2088–2102 (2010).  ? ? ?
22. Mendoza-Vargas, A. et al. Genome-Wide Identification of Transcription  ? ? ?
Start Sites, Promoters and Transcription Factor Binding Sites in E. coli.  ? ? ?
PLOS ONE 4, e7526 (2009).  ? ? ?
23. Membrillo-Hernández, J. et al. Evolution of the adhE Gene Product  ? ? ?
ofEscherichia coli from a Functional Reductase to a Dehydrogenase  ? ? ?
GENETIC AND BIOCHEMICAL STUDIES OF THE MUTANT PROTEINS.  ? ? ?
J. Biol. Chem. 275, 33869–33875 (2000).  ? ? ?
24. Kessler, D., Leibrecht, I. & Knappe, J. Pyruvate-formate-lyase- ? ? ?
deactivase and acetyl-CoA reductase activities of Escherichia coli reside on  ? ? ?
a polymeric protein particle encoded by adhE. FEBS Lett. 281, 59–63  ? ? ?
(1991).  ? ? ?
25. Shasmal, M., Dey, S., Shaikh, T. R., Bhakta, S. & Sengupta, J. E. coli  ? ? ?
metabolic protein aldehyde-alcohol dehydrogenase-E binds to the  ? ? ?
ribosome: a unique moonlighting action revealed. Sci. Rep. 6, 19936  ? ? ?
(2016).  ? ? ?
26. Ma, D., Alberti, M., Lynch, C., Nikaido, H. & Hearst, J. E. The local  ? ? ?
repressor AcrR plays a modulating role in the regulation of acrAB genes of  ? ? ?
Escherichia coli by global stress signals. Mol. Microbiol. 19, 101–112  ? ? ?
(1996).  ? ? ?
 17 
27. Okusu, H., Ma, D. & Nikaido, H. AcrAB efflux pump plays a major role  ? ? ?
in the antibiotic resistance phenotype of Escherichia coli multiple-antibiotic- ? ? ?
resistance (Mar) mutants. J. Bacteriol. 178, 306–308 (1996).  ? ? ?
28. Wang, H., Dzink-Fox, J. L., Chen, M. & Levy, S. B. Genetic  ? ? ?
Characterization of Highly Fluoroquinolone-Resistant Clinical Escherichia  ? ? ?
coli Strains from China: Role of acrR Mutations. Antimicrob. Agents  ? ? ?
Chemother. 45, 1515–1521 (2001).  ? ? ?
29. Cooper, T. F., Rozen, D. E. & Lenski, R. E. Parallel changes in gene  ? ? ?
expression after 20,000 generations of evolution in Escherichia coli. Proc.  ? ? ?
Natl. Acad. Sci. 100, 1072–1077 (2003).  ? ? ?
30. Hale, L., Lazos, O., Haines, A. & Thomas, C. An efficient stress-free  ? ? ?
strategy to displace stable bacterial plasmids. BioTechniques 48, 223–228  ? ? ?
(2010).  ? ? ?
31. Møller, T. S. B. et al. Relation between tetR and tetA expression in  ? ? ?
tetracycline resistant Escherichia coli. BMC Microbiol. 16, 39 (2016).  ? ? ?
32. Ramos, J. L. et al. The TetR Family of Transcriptional Repressors.  ? ? ?
Microbiol. Mol. Biol. Rev. 69, 326–356 (2005).  ? ? ?
33. Allard, J. D. & Bertrand, K. P. Membrane topology of the pBR322  ? ? ?
tetracycline resistance protein. TetA-PhoA gene fusions and implications  ? ? ?
for the mechanism of TetA membrane insertion. J. Biol. Chem. 267, 17809– ? ? ?
17819 (1992).  ? ? ?
34. Orth, P., Schnappinger, D., Hillen, W., Saenger, W. & Hinrichs, W.  ? ? ?
Structural basis of gene regulation by the tetracycline inducible Tet  ? ? ?
repressor–operator system. Nat. Struct. Mol. Biol. 7, 215–219 (2000).  ? ? ?
 18 
35. Nguyen, T. N., Phan, Q. G., Duong, L. P., Bertrand, K. P. & Lenski, R.  ? ? ?
E. Effects of carriage and expression of the Tn10 tetracycline-resistance  ? ? ?
operon on the fitness of Escherichia coli K12. Mol. Biol. Evol. 6, 213–225  ? ? ?
(1989).  ? ? ?
36. Stoesser, N. et al. Evolutionary History of the Global Emergence of the  ? ? ?
Escherichia coli Epidemic Clone ST131. mBio 7, e02162-15 (2016).  ? ? ?
37. Johnson, T. J. et al. Separate F-Type Plasmids Have Shaped the  ? ? ?
Evolution of the H30 Subclone of Escherichia coli Sequence Type 131.  ? ? ?
mSphere 1, e00121-16 (2016).  ? ? ?
38. Crozat, E., Philippe, N., Lenski, R. E., Geiselmann, J. & Schneider, D.  ? ? ?
Long-Term Experimental Evolution in Escherichia coli. XII. DNA Topology  ? ? ?
as a Key Target of Selection. Genetics 169, 523–532 (2005).  ? ? ?
39. Li, H. & Durbin, R. Fast and accurate short read alignment with  ? ? ?
Burrows-Wheeler transform. Bioinforma. Oxf. Engl. 25, 1754–1760 (2009).  ? ? ?
40. McKenna, A. et al. The Genome Analysis Toolkit: A MapReduce  ? ? ?
framework for analyzing next-generation DNA sequencing data. Genome  ? ? ?
Res. 20, 1297–1303 (2010).  ? ? ?
41. Cingolani, P. et al. A program for annotating and predicting the effects  ? ? ?
of single nucleotide polymorphisms, SnpEff. Fly (Austin) 6, 80–92 (2012).  ? ? ?
42. Robinson, J. T. et al. Integrative genomics viewer. Nat. Biotechnol. 29,  ? ? ?
24–26 (2011).  ? ? ?
43. Chen, K. et al. BreakDancer: an algorithm for high-resolution mapping  ? ? ?
of genomic structural variation. Nat. Methods 6, 677–681 (2009).  ? ? ?
44. Anderson, M. J. Distance-Based Tests for Homogeneity of Multivariate  ? ? ?
Dispersions. Biometrics 62, 245–253 (2006).  ? ? ?
 19 
45. Anderson, M. J. A new method for non-parametric multivariate analysis  ? ? ?
of variance. Austral Ecol. 26, 32–46 (2001).  ? ? ?
46. Zapala, M. A. & Schork, N. J. Multivariate regression analysis of  ? ? ?
distance matrices for testing associations between gene expression  ? ? ?
patterns and related variables. Proc. Natl. Acad. Sci. 103, 19430–19435  ? ? ?
(2006).  ? ? ?
  ? ? ?
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Methods  ? ? ?
Strains, culture conditions and evolution experiment  ? ? ?
E. coli MG1655 chromosomally labelled with GFP at the attB lambda  ? ? ?
attachment site was used in the evolution experiments. Isogenic E. coli  ? ? ?
MG1655-mCherry was used as a reference strain in competition and  ? ? ?
conjugation rate experiments. Both E. coli strains were provided by the Van  ? ? ?
Der Woude lab (University of York). The RK2 plasmid was introduced to the  ? ? ?
strains through conjugation from E. coli MV10 provided by the Thomas lab  ? ? ?
(University of Birmingham). All cultures were grown in Oxiod® Nutrient Broth  ? ? ?
(NB) at 37°C 5 ml in 50 ml microcosms shaken at 180 rpm. Independent  ? ? ?
selection lines were founded by 30 independent single colonies of E. coli  ? ? ?
MG1655-GFP harbouring RK2. These were grown overnight in non-selective  ? ? ?
conditions and split into the 5 antibiotic treatments, no antibiotic selection, 100  ? ? ?
ȝg/ml ampicillin, 10 ȝg/ml tetracycline, 100 ȝg/ml ampicillin plus 10 ȝg/ml  ? ? ?
tetracycline, and 24 hour cycling between 100 ȝg/ml ampicillin and 10 ȝg/ml  ? ? ?
tetracycline, with 6 replicate populations per treatment. In parallel, 6  ? ? ?
 20 
independent E. coli MG1655-GFP colonies were picked for control treatments  ? ? ?
and grown under no selection. Selection lines were established by transferring  ? ? ?
50 ȝl of saturated overnight culture into 5ml of selective media. These  ? ? ?
populations were maintained through transfer of 1% of the population into  ? ? ?
fresh media and antibiotics every 24 hours for 80 transfers, resulting in ~6.64  ? ? ?
generations per day, totalling ~530 bacterial generations. For the cycling  ? ? ?
treatment 3 populations were initiated with 100ȝg/ml ampicillin and 3  ? ? ?
populations were initiated with 10ȝg/ml tetracycline. Culture density (OD600)  ? ? ?
was recorded every 24 hours. Plasmid prevalence was measure at the start  ? ? ?
and end of the selection experiment by screening 20 randomly picked  ? ? ?
colonies from each population using multiplex primers specific to RK2  ? ? ?
replication origin (Fw: ctcatctgtcaacgccgc, Rv: aaccggctatgtcgtgct), ȕ- ? ? ?
lactamase (Fw: ataactacgatacgggagggc, Rv: acatttccgtgtcgccctta), and  ? ? ?
tetracycline efflux pump (Fw: tgggttctctatatcgggcg,Rv: tgggcgagtgaatgcagaat).  ? ? ?
These primers allowed for the detection of plasmid loss and transposition of  ? ? ?
resistances onto the chromosome. One end point clone was randomly  ? ? ?
selected from each population for phenotypic typing, curing, calculation of  ? ? ?
MICs and sequencing. Every eight transfers throughout the experiment 500 ȝl  ? ? ?
samples of whole populations were collected and stored in 25% glycerol at - ? ? ?
80°C. Whole populations were also plated out on non-selective media, 20  ? ? ?
individual clones were then randomly selected, sub-cultured for a further 24  ? ? ?
hours in non-selective media, and stored in 25% glycerol in 96 well plates.  ? ? ?
  ? ? ?
Relative Fitness   ? ? ?
 21 
The relative fitness of the evolved plasmid bearing versus ancestral plasmid  ? ? ?
free strain was estimated by direct competition, with six replicate strains per- ? ? ?
treatment. The competitions were initiated with 50 ȝl of 1:1 mixtures of  ? ? ?
plasmid-bearing evolved strain and plasmid-bearing ancestral strain marked  ? ? ?
with mCherry from overnight cultures in 5ml of non-selective NB media. The  ? ? ?
relative fitness of the evolved strains was calculated by gaining exact viable  ? ? ?
cell counts at 0 hours and 24 hours, strains were distinguished through  ? ? ?
detection of fluorescent markers using Zeis Stereo Lumar v12 microscope.  ? ? ?
The relative fitness of plasmid-bearing bacteria was calculated as a ratio of  ? ? ?
Malthusian parameters38:   ? ? ?
௘ܹ௩௢ ൌ  ൬ ௙ܰ௜௡௔௟ǡ௘௩௢௜ܰ௡௜௧௔௟ǡ௘௩௢൰ ൬ ௙ܰ௜௡௔௟ǡ௔௡௖௜ܰ௡௜௧௔௟ǡ௔௡௖൰
  ? ? ?
Fitness effects due to different markers was determined by competing plasmid  ? ? ?
free MG1655-GFP with plasmid free MG1655-mCherry, the relative fitness of  ? ? ?
MG1655-GFP was not significantly difference from 1 (t5=0.015584, p=0.9882)  ? ? ?
showing that there is no significant difference between the two marker strains.  ? ? ?
  ? ? ?
Relative fitness of evolved strains harbouring evolved plasmid or evolved  ? ? ?
strains harbouring ancestral plasmid versus ancestral plasmid bearing cells  ? ? ?
was estimated using the same method as above, with eighteen replicate  ? ? ?
strains per competition, but grown in 100 ȝl cultures in a 96 well plate, 37°C  ? ? ?
shaken at 600 rpm, 3 mm orbital radius, inoculated to an initial dilution of  ? ? ?
1:500. Again no fitness effect of markers was observed (t5=-0.2795, p=0.791).  ? ? ?
  ? ? ?
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Curing RK2 from evolved strains  ? ? ?
Evolved strains were cured using the pCURE curing system30. The anti-incP-1  ? ? ?
cassette (RK2 oriV, parD, korA, and incC genes) from pCURE11 was ligated  ? ? ?
into the pLAZ2 chloramphenicol resistant vector that contains the sacB gene  ? ? ?
allowing counter selection for plasmid free segregants. The resultant plasmid  ? ? ?
was transformed into chemically competent evolved strains and selected for  ? ? ?
using Cml 12.5 ȝg/ml. Single colony transformants were re-streaked on to  ? ? ?
Cml 12.5 ȝg/ml plates and Cml 12.5 ȝg/ml + 5% sucrose. Sucrose sensitive  ? ? ?
colonies were checked by PCR for the presence of the curing plasmid (Fw:  ? ? ?
aagttttggtgactgcgctc, Rv: caaagacgatgtggtagccg) and absence of RK2 ȕ- ? ? ?
lactamase and tetA (primers as above). Successfully cured clones were  ? ? ?
cultured for 24 hours in non-selective media to allow segregation of the curing  ? ? ?
plasmid; sergeants were selected on antibiotic free, 5% sucrose plates. To  ? ? ?
confirm loss of both plasmids sucrose resistant colonies were check for  ? ? ?
sensitivity to chloramphenicol, ampicillin, and tetracycline, as well as PCR  ? ? ?
using primers mentioned above. Both the ancestral strain harbouring RK2 and  ? ? ?
ancestral plasmid free strains under went the curing process and were used  ? ? ?
as a comparison to cured evolved strains to control for curing process.  ? ? ?
Ancestral RK2 was introduced into the cured evolved strains, and evolved  ? ? ?
RK2 was introduced into the plasmid free ancestor though conjugation. Again,  ? ? ?
to control for the curing and conjugation steps, ancestral RK2 was conjugated  ? ? ?
into cured ancestral strains and used for comparison. Saturated overnight  ? ? ?
cultures of donor plasmid containing strains and recipient plasmid free strains  ? ? ?
were mixed 1:1, and 50 ȝl was used to inoculate 5ml NB. The mixed cultures  ? ? ?
were grown for 24 hours and plated out on to 100 ȝg/ml ampicillin to select for  ? ? ?
 23 
transconjugants. Transconjugants were confirmed by fluoresces and PCR  ? ? ?
screening for RK2 plasmid.   ? ? ?
  ? ? ?
MIC  ? ? ?
To measure minimal inhibitory concentrations, six replicate cultures per- ? ? ?
treatment were grown overnight until stationary phase in 5 ml NB, the  ? ? ?
saturated cultures were then sub-cultured 50 ȝl into 5 ml fresh NB and grown  ? ? ?
to an OD600 of 0.5. These were then diluted into 96-well plates containing a  ? ? ?
log2 serial dilution of antibiotic (AMP, TET or CML) to an initial density of  ? ? ?
5×105 CFU/ml. 100 ȝl cultures were grown for 24 hours 37°C shaken at 600  ? ? ?
rpm, 3 mm orbital radius. OD600 was measured after 24 hours.  ? ? ?
  ? ? ?
Growth Curves  ? ? ?
Six replicate saturated overnight cultures per-treatment were sub-cultured to  ? ? ?
an OD600 of 0.5, and used to inoculate 100 ȝl NB supplemented with 10 ȝg/ml  ? ? ?
TET per well in 96-well plates at a final dilution of 1:1000. Plates were grown  ? ? ?
at 37°C with shaking at 300 rpm, 3 mm orbital radius for 24 hours, OD600 was  ? ? ?
measured every 16 minutes by Tecan infinite M200 Pro plate reader. Growth  ? ? ?
rates were calculated as the maximum slope of log2 transformed OD600  ? ? ?
covering four time points (~1 hour of growth), lag phase was calculated to end  ? ? ?
when growth rate reached 10% of the maximum achieved growth rate.  ? ? ?
  ? ? ?
Genome sequencing and analysis  ? ? ?
Whole genomes were extracted from each evolved population’s clone as well  ? ? ?
as the ancestral strain and ancestral strain harbouring the RK2 plasmid using  ? ? ?
 24 
the DNeasy Blood and Tissue extraction kit (Qiagen). The total DNA was  ? ? ?
sequenced by MicrobesNG (http://www.microbesng.uk), which is supported  ? ? ?
by the BBSRC (grant number BB/L024209/1), using Illumnia MiSeq. Reads  ? ? ?
were mapped to E. coli MG1655 K-12 genome (GenBank accession  ? ? ?
U00096.3) and RK2 (GenBank accession BN000925.1) reference using BWA- ? ? ?
MEM39. Single nucleotide variants and small indel events were detected using  ? ? ?
GATK UnifiedGenotyper40 and SnpEff41, insertion sequences were identified  ? ? ?
using custom scripts and Integrative Genomics Viewer42, and large genome- ? ? ?
wide structural variants were detected using BreakDancer43. Mutations that  ? ? ?
were present in the ancestral clones were excluded, resulting in a set of  ? ? ?
mutations that were acquired during the selection experiment.  ? ? ?
  ? ? ?
Tracking mutations  ? ? ?
Populations that did not show a hypermutator phenotype, had insertion  ? ? ?
sequences within ompF, and mutations in the tetracycline resistance genes  ? ? ?
on the plasmid, from the constant TET treatments (T and AT treatments) were  ? ? ?
selected for further analysis to gain an understanding of the mutational  ? ? ?
timeline during the selection experiment. Insertion sequences within ompF  ? ? ?
were identified within whole populations of T4, AT2, AT3 and AT5 by PCR of  ? ? ?
the ompF gene (Fw: ACTTCAGACCAGTAGCCCAC, Rv:  ? ? ?
GCGCAATATTCTGGCAGTGA). A short product of 716 bp indicated no  ? ? ?
insertion sequence, a long product of 1484 bp indicted IS1 and a long product  ? ? ?
of 1911 bp indicted IS5. Whole population PCR indicated that ompF::IS  ? ? ?
mutants had swept into the population by transfer 40 for populations T4, AT2  ? ? ?
and AT5, and transfer 48 in population AT3. Frequency of ompF insertion  ? ? ?
 25 
sequences were calculated by PCR of 20 clones from transfers 8, 16, 24, 32,  ? ? ?
and 40. Tetracycline resistance genes (tetA and tetR) from clones containing  ? ? ?
ompF::IS mutations from population AT2, transfers 8, 16, 24, and 32 were  ? ? ?
then Sanger sequenced to determine if ompF mutations arise before tetAR  ? ? ?
mutations (tetA: Fw: GGCTGCAACTTTGTCATG,Rv:  ? ? ?
TTCCAACCGCACTCCTAG, Internal1: ACAGCGCCTTTCCTTTG, Interal2:  ? ? ?
AAGGCAAGCAGGATGTAG; tetR: Fw: TCTGACGCGGTGGAAAG, Rv:  ? ? ?
ACGCGCGGATTCTTTATC, Internal1: GAGCCTGTTCAACGGTG, Internal2:  ? ? ?
TCTGACGACACGCAAAC).  ? ? ?
  ? ? ?
Statistical analysis  ? ? ?
To test if the mutations observed within each treatment had significantly  ? ? ?
different variances a multivariate homogeneity of groups variances test was  ? ? ?
conducted44. The binary presence or absence of a variant at each allele was  ? ? ?
use to calculate a Euclidean distance matrix between each population. This  ? ? ?
was used to test for homogeneity of variances between treatments using  ? ? ?
betadisper {vegan 2.4-0}. The variances between treatments were  ? ? ?
significantly different, with hypermutators significantly affecting within-group  ? ? ?
variation. These clones were removed from further analysis as significant  ? ? ?
differences in within-group variance can lead to falsely significant results  ? ? ?
when testing for differences between groups45. Permutational Multivariate  ? ? ?
Analysis of Variance was used to calculate whether different evolutionary  ? ? ?
treatments resulted in different sets of mutations45,46. Using the Euclidean  ? ? ?
distance matrix with hypermutators removed, the significance of within- and  ? ? ?
between-group distances was calculated using adonis2 {vegan 2.4-0}. The  ? ? ?
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data was partitioned into different groups, multiple testing was corrected for  ? ? ?
using Bonferroni correction. Neighbour Joining phylogeny was constructed  ? ? ?
using the binary presence or absence table with hypermutators removed.  ? ? ?
Tree estimation and bootstrap support was conducted using ape-package  ? ? ?
{ape 4.0}. Significant difference between two related samples was calculated  ? ? ?
using two sided, two-sample t-test. Shapiro-Wilk test was conducted to check  ? ? ?
for normality, when normality could not be assumed a non-parametric  ? ? ?
Wilcoxon signed-rank test was used. Differences among treatments growth  ? ? ?
under antibiotic selection were calculated by ANOVA of the integral of the  ? ? ?
resistance profiles, with subsequent Tukey multiple comparison of means. All  ? ? ?
statistical analysis was conducted in R (version 3.2.3).  ? ? ?
  ? ? ?
Data Availability  ? ? ?
The sequence data supporting the findings of this study are available at the  ? ? ?
European Nucleotide Archive, accession: PRJEB20735. All other data in this  ? ? ?
study is available at Figshare data depository  ? ? ?
(https://doi.org/10.6084/m9.figshare.5092225.v1). Custom code used to map  ? ? ?
possible IS elements are available online  ? ? ?
(https://github.com/mbottery/Co_Evo_IS_Analysis).  ? ? ?
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Figure 1 | Resistance profiles of evolved plasmids and hosts. Growth of  ? ? ?
a, evolved MG1655 strains with evolved RK2 plasmids b, evolved MG1655  ? ? ?
strains cured of evolved RK2 plasmids c, evolved MG1655 strains with  ? ? ?
ancestral RK2 plasmid and d, ancestral MG1655 clones with evolved RK2  ? ? ?
plasmids in the presence of tetracycline, ampicillin or chloramphenicol in  ? ? ?
comparison to ancestral MG1655. Points represent means of one clone from  ? ? ?
each of the six independent treatment populations, with SEM error bars.  ? ? ?
Dashed grey and black lines show the resistance profiles of plasmid free and  ? ? ?
plasmid containing ancestral strains respectively. Dashed lines in evolved  ? ? ?
host cured of plasmid plots (c) show ancestral MG1655 and ancestral  ? ? ?
 28 
MG1655(RK2) after curing process. Dashed lines in ancestral host evolved  ? ? ?
plasmid plots (d) show ancestral MG1655 and ancestral MG1655(RK2) which  ? ? ?
had under gone curing with ancestral RK2 subsequently reintroduced.   ? ? ?
Vertical dashed lines in AMP and TET resistance profiles show the  ? ? ?
concentrations of AMP (100 ȝg/ml) or TET (10 ȝg/ml) used in the selection  ? ? ?
experiment.  ? ? ?
  ? ? ?
Figure 2 | Mutations show treatment specific parallelism. a, An unrooted  ? ? ?
neighbour joining phylogeny of end-point evolved clones. The distance matrix  ? ? ?
was constructed from the binary presence or absence of variants at each  ? ? ?
gene relative to the ancestral strain; hypermutators were excluded from the  ? ? ?
analysis. Scale bar represents number of gene variants; percentage bootstrap  ? ? ?
support is shown at the branches, B=1000, values below 0.3 are omitted. Blue  ? ? ?
branches represent clone isolated from TET treatments. b, Mutations  ? ? ?
observed in evolved clones (excluding hypermutators) across treatment.  ? ? ?
Rings represent E. coli chromosomes or RK2 plasmids. Dots represent  ? ? ?
mutations, the size of the dots represent the number of mutations at the same  ? ? ?
loci across independent replicate populations. Plots of individual treatments  ? ? ?
are in Supplementary Fig. 3.   ? ? ?
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